AHL
ACAD icon

Abel Hall LLC’s Acadia Pharmaceuticals ACAD Stock Holding History

Abel Hall LLC’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$321K Sell
12,694
-1,561
-11% -$34.3K 0.06% 444
2026
Q1 		$317K Buy
14,255
+4,182
+42% +$99.9K 0.07% 383
2025
Q4 		$269K Buy
+10,073
New +$241K 0.06% 387

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Abel Hall LLC's ACAD Position: Q2 2026 in Review

Abel Hall LLC reduced its Acadia Pharmaceuticals (ACAD) stake by 11% in Q2 2026, selling an estimated $34.3K and leaving 12,694 shares worth $321K. The position accounts for 0.06% of the portfolio, ranked #444.

Abel Hall LLC first reported a position in ACAD in Q4 2025 and has held it in 3 quarters since. 353 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

  • Abel Hall LLC held 12,694 shares of Acadia Pharmaceuticals worth $321K as of Q2 2026.
  • Abel Hall LLC sold 1,561 Acadia Pharmaceuticals shares in Q2 2026, an estimated $34.3K.
  • Acadia Pharmaceuticals made up 0.06% of Abel Hall LLC's portfolio in Q2 2026, its #444 holding.
  • Abel Hall LLC first reported a position in Acadia Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • 353 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Abel Hall LLC's 13F filing for Q2 2026, filed 24 Jul 2026.